Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus CYCLOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus CYCLOCORT.
CARMOL HC vs CYCLOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid